STDs in the LGBTQ+ Community: Unique Challenges and Resources

LGBTQ+ individuals face a distinct set of STD-related challenges that are not adequately addressed by general sexual health guidance. Higher STD prevalence in some LGBTQ+ communities is not a moral failing or an inherent biological fact — it is the predictable result of systemic factors: historical exclusion from mainstream healthcare, stigma that deters testing, and sexual health education that has consistently failed to address same-sex and gender-diverse sexuality. Understanding these factors is essential to understanding the actual risk landscape.

Why STD Rates Differ Across LGBTQ+ Communities

Gay and bisexual men have substantially higher rates of HIV, syphilis, gonorrhea, and chlamydia than the general population. The CDC estimates that MSM account for approximately 70% of new HIV diagnoses in the US despite being roughly 4% of the male population. This disparity is driven by network effects (higher prevalence within social and sexual networks increases individual exposure risk), biological factors (receptive anal intercourse carries a higher per-act HIV transmission risk than vaginal intercourse), and structural factors including historical underdiagnosis and undertreatment.

Lesbian and bisexual women are sometimes assumed to be at low STD risk, which is incorrect. HSV-1, HPV, trichomoniasis, and bacterial vaginosis can all be transmitted through female-to-female sexual contact. Many clinicians fail to ask about same-sex partners, leading to missed diagnoses. Transgender individuals face distinct patterns of risk depending on anatomy, sexual practices, and gender-affirming treatments, and often encounter healthcare providers who lack the knowledge to assess or address their specific needs.

Specific Infections and LGBTQ+ Risk Profiles

HIV

PrEP (pre-exposure prophylaxis) is highly effective at preventing HIV when taken consistently, reducing transmission risk by more than 99% for sexual transmission. Despite this, uptake among people who could benefit most remains uneven. All MSM who are HIV-negative and sexually active should discuss PrEP with a clinician. PrEP is also recommended for transgender women with ongoing exposure risk. Insurance coverage for PrEP has improved significantly but remains a barrier for some.

Syphilis

Syphilis rates in the US have increased dramatically in recent years, with MSM disproportionately affected. Syphilis can present subtly — the primary chancre is often painless and may go unnoticed, particularly in rectal or pharyngeal locations. Annual syphilis screening is recommended for sexually active MSM; more frequent screening (every 3–6 months) is recommended for those with multiple partners or other risk factors.

Gonorrhea and chlamydia

Both can infect the urethra, rectum, and pharynx (throat). Rectal and pharyngeal infections are commonly asymptomatic. A urine test alone will not detect rectal or throat infections — site-specific swabs are required. Clinicians who only offer urine testing to MSM patients are providing inadequate care.

Mpox (monkeypox)

The 2022 mpox outbreak disproportionately affected MSM networks globally. Mpox is transmitted through close physical contact, including sexual contact. Vaccination (JYNNEOS) is available and recommended for people at ongoing risk. Testing is available at many sexual health clinics and some primary care providers.

Barriers to Care in LGBTQ+ Communities

Fear of judgment or discrimination in clinical settings remains a significant barrier for many LGBTQ+ individuals. A 2023 survey found that more than a third of LGBTQ+ adults reported delaying or avoiding healthcare due to anticipated discrimination. LGBTQ+-specific sexual health clinics and organisations typically provide care without these barriers and have staff trained in LGBTQ+-relevant sexual health. If your primary care provider is not asking about your sexual practices in a way that reflects your actual risk profile, consider accessing care through a specialist sexual health service.

Recommended Screening Frequency

For sexually active MSM, the CDC recommends at minimum annual testing for HIV, syphilis, gonorrhea (urethra and pharynx), and chlamydia (urethra, pharynx, and rectum). More frequent testing (every 3–6 months) is appropriate for those with multiple partners, inconsistent condom use, or a history of STDs. For lesbian and bisexual women and transgender individuals, screening recommendations should be tailored to anatomy, sexual practices, and risk factors in discussion with a knowledgeable clinician.

When to Seek Care

• Any genital, rectal, or pharyngeal symptoms — sores, discharge, pain, rash — warrant same-day evaluation. Don't wait for a scheduled appointment.

• After a potential HIV exposure: PEP (post-exposure prophylaxis) must be started within 72 hours to be effective. Go to an ER or sexual health clinic immediately if you believe you've had a high-risk HIV exposure.

• If you haven't been tested in over 6 months and are sexually active: book a test. Asymptomatic infections are the norm, not the exception.

Frequently Asked Questions

Do lesbian women need STD testing?

Yes. Female-to-female transmission of HSV-1, HPV, trichomoniasis, and bacterial vaginosis is documented. Lesbian women are at lower risk for some STDs than heterosexual women or MSM, but lower risk does not mean no risk. Any sexually active person benefits from periodic testing, and the specific tests should reflect their actual sexual practices.

Is PrEP only for gay men?

No. PrEP is recommended for any HIV-negative person at ongoing substantial risk of HIV exposure, regardless of sexual orientation or gender identity. This includes heterosexual women with HIV-positive partners, people who inject drugs, and transgender individuals with ongoing risk. Access to PrEP is a sexual health equity issue, not a gay health issue.

Can transgender women get STDs?

Yes. Transgender women who have sex with men are among the groups at highest risk for HIV globally, with prevalence rates substantially higher than in cisgender women. Transgender women should have access to the same PrEP discussions, STD screening, and preventive care as any other patient at risk. Gender-affirming hormone therapy does not affect STD transmission risk.

What if my doctor doesn't ask about same-sex partners?

You can tell them directly. Simply saying "I have sex with men" or "I have female partners" gives your provider the information they need to recommend appropriate testing. If your provider seems uncomfortable or provides inadequate care as a result, accessing care at an LGBTQ+-friendly sexual health clinic is a practical alternative.

Get Tested

Same-day confidential testing, including site-specific swabs and HIV testing, is available at locations across the US. In Texas: Houston and Dallas. In Florida: Jacksonville. On the West Coast: Los Angeles. In the mid-Atlantic: Washington DC.

Related reading: HIV Prevention and PrEP · LGBTQ+ STD Testing Guidelines · Asymptomatic STDs